Latest Comments

EMA withdrawal threatens UK patient access to cutting edge therapies

EMA withdrawal threatens UK patient access to cutting edge therapies

Improved and affordable diagnostics for kidney transplant rejection

Improved and affordable diagnostics for kidney transplant rejection

Progress for the CF community in April

Progress for the CF community in April

Unmet needs in melanoma treatment

Unmet needs in melanoma treatment

Viability of GSK’s Mosquirix hinges on key pilot study for malaria prevention

Viability of GSK’s Mosquirix hinges on key pilot study for malaria prevention

Verily aims to become a prophet of human health

Verily aims to become a prophet of human health

Where you live matters: geographic differences in DAA treatment access

Where you live matters: geographic differences in DAA treatment access

Quality-of-life improvements: DAA treatment from the patient’s perspective

Quality-of-life improvements: DAA treatment from the patient’s perspective

AbbVie impresses with solid clinical data for its newest DAA regimen

AbbVie impresses with solid clinical data for its newest DAA regimen

CRISPR: are genetic mutants the future of disease treatment?

CRISPR: are genetic mutants the future of disease treatment?

FMT therapy from Rebiotix achieves positive Phase II results for recurrent C. difficile

FMT therapy from Rebiotix achieves positive Phase II results for recurrent C. difficile

Trulance sNDA submission for IBS-C: a step forward for Synergy Pharmaceuticals

Trulance sNDA submission for IBS-C: a step forward for Synergy Pharmaceuticals

Rethinking future treatment options for sepsis: from immunosuppressive to immunostimulating drugs

Rethinking future treatment options for sepsis: from immunosuppressive to immunostimulating drugs

Hope for sufferers with extremely rare form of liver cancer

Hope for sufferers with extremely rare form of liver cancer

AD/PD 2017 conference coverage: Future directions for Alzheimer's drug development

AD/PD 2017 conference coverage: Future directions for Alzheimer's drug development

AD/PD conference coverage: How to succeed in late-phase Alzheimer’s research

AD/PD conference coverage: How to succeed in late-phase Alzheimer’s research

Type 2 Diabetes 'me-too drugs': a blessing or a curse?

Type 2 Diabetes 'me-too drugs': a blessing or a curse?

FOURIER outcomes data highlights the importance of value in drug development

FOURIER outcomes data highlights the importance of value in drug development

Unmet needs in the liver cancer market mean it’s full of potential

Unmet needs in the liver cancer market mean it’s full of potential

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

Amgen and Cytokinetics: approaching acute heart failure from a different angle

Amgen and Cytokinetics: approaching acute heart failure from a different angle